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SUMMARY
6-thioguanine (6TG) has become the ‘ugly sister’ of azathioprine and 6-mercaptopurine 
since it has been associated with sinusoidal obstruction syndrome (SOS) of the liver. 
Although the overall toxicity profile of 6TG seems superior to that of the other thio-
purines, further use of 6TG was largely discarded due to fear of this complication and 
related hepatic nodular regenerative hyperplasia and veno-occlusive disease. There is 
emerging evidence showing that 6TG-associated SOS is a dose-dependent and reversible 
phenomenon. Therefore, it is urged that the use of 6TG in inflammatory bowel disease 
be reconsidered; randomized controlled studies are warranted.
Keywords: 6-thioguanine; sinusoidal obstruction syndrome; veno-occlusive disease; 
nodular regenerative hyperplasia; leukemia; inflammatory bowel disease.
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RESUMO
A tioguanina está associada à síndrome da obstrução sinusoidal 
evitável? Lições aprendidas com a 6-tioguanina no tratamento da 
doença inflamatória intestinal em modelo de ratos
A 6-tioguanina (6TG) tornou-se “a irmã feia” da azatioprina e da 6-mercaptopurina, pois 
tem sido associada à “síndrome da obstrução sinusoidal” (SOS) do fígado. Embora o per-
fil de toxicidade geral da 6TG talvez seja superior ao de outras tiopurinas, a continuação 
do uso de 6TG foi amplamente descartada devido ao medo dessa complicação e das rela-
cionadas à hiperplasia hepática nodular regenerativa e doença veno-oclusiva. Evidências 
emergentes demonstram que a SOS associada à 6TG é um fenômeno dose-dependente 
que pode ser revertido. Portanto, é urgente que o uso do 6TG na doença inflamatória 
intestinal seja reconsiderado; são necessários estudos randomizados e controlados.
Unitermos: 6-tioguanina; síndrome da obstrução sinusoidal; doença oclusiva venosa; 
hiperplasia nodular regenerativa; leucemia; doença inflamatória intestinal.
©2012 Elsevier Editora Ltda. Todos os direitos reservados.
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INTRODUCTION
6-thioguanine (6TG) is the ugly sister of the thiopurines, 
azathioprine (AZA) and 6-mercaptopurine (6MP), because 
of its strong association with sinusoidal obstruction syn-
drome (SOS) of the liver, previously named and overlapping 
with veno-occlusive disease (VOD) and nodular regenera-
tive hyperplasia (NRH). The first cases of SOS attributed to 
6TG were reported in 19821,2, although the possibility had 
been raised earlier in the literature3. Those of us who em-
barked on 6TG treatment for inflammatory bowel disease 
(IBD) in the beginning of the 21st century either did not 
know of this literature or had forgotten it. However, shortly 
after the initial enthusiasm for 6TG in IBD, the gastroen-
terological world was reminded of SOS by Dubinsky et al.4, 
in what has become an influential study. These investigators 
concluded that SOS was idiosyncratic, rather than dose-
related, and that it was therefore unsafe to use 6TG at any 
dose. The manuscript has many problems including not 
least that the dose of 6TG in its patients was never well char-
acterized, but notwithstanding most other groups have been 
wary of using 6TG since the publication of this paper and 
especially given that there is no reliable test for SOS.
There is also a widely held concern that SOS is irre-
versible, although interestingly one of the earliest detailed 
reports of 6TG-induced SOS concluded on the basis of 
sequential liver histology that SOS was to a large degree 
reversible2.  More recently, a concern has been raised that 
SOS may be a thiopurine class effect5, although the rate of 
SOS with AZA or 6MP does not seem to be different from 
that in the background population. 
SINUSOIDAL OBSTRUCTION SYNDROME
Ongoing sinusoidal obstruction syndrome (SOS) manifests 
in time with various degrees of tender hepatomegaly, asci-
tes, hyperbilirubinemia, persistent thrombocytopenia, and 
increased portal venous pressure, which in turn may give 
rise to splenomegaly, esophageal varices and their compli-
cations. While the pathogenesis is not completely under-
stood, sinusoidal endothelial injury resulting in the loss 
of sinusoidal wall integrity is believed to play a significant 
role. Intrasinusoidal cytotoxic CD8+ T lymphocytes seem 
to be involved6. Histopathological findings include sinu-
soidal dilatation with accumulation of erythrocytes in both 
the sinusoids and the perisinusoidal spaces (space of Disse). 
Specific morphological abnormalities such as peliosis hepa-
tis and nodular regenerative hyperplasia (NRH) frequently 
accompany SOS, likely reflecting a common pathogenesis7.
6-THIOGUANINE, SINUSOIDAL OBSTRUCTION SYNDROME 
AND IBD
In 1966, more than ten years after its discovery, 6TG was first 
used in the treatment of IBD. Its therapeutic efficacy seemed 
promising, albeit nausea, sensory loss with unsteadiness of 
gait or liver test abnormalities necessitated therapy with-
drawal in these patients8. 6TG was then not used in IBD 
treatment until its reintroduction around 2001, when Du-
binsky et al. reported on its successful use in Crohn’s disease 
patients who had failed conventional thiopurine therapy9. 
Following their promising results, other researchers began 
to use 6TG in IBD treatment, mostly with success. Although 
a controlled clinical trial was never performed, available 
studies showed 6TG efficacy (Table 1) and tolerability (Ta-
ble 2) to be favorable. In 2003, however, the use of 6TG in 
IBD patients was linked with NRH; and as a consequence 
further use was discouraged4. Other researchers appeared to 
corroborate the association between the use of 6TG in IBD 
and the occurrence of NRH/ VOD/ SOS.
Seiderer et al.10 reported NRH in 16 out of 45 liver 
biopsies from a selected group of IBD patients using 
6TG after failing conventional thiopurine treatments. 
Author n IBD
Daily dose
(mg)
Duration
(months)
Response*
(%)
Reference
(nr)
Dubinsky et al.9 10 CD 40 4 70% (9)
Cheung et al.24 15 CD+UC 80 3 73% (24)
Dubinsky et al.25 21 CD+UC 20-40 9 88% (25)
Herrlinger et al.26 39 CD 40-80 6 87% (26)
Herrlinger et al.27 16 CD 20-40 12 83% (27)
Bonaz et al.28 49 CD 20 12 79% (28)
Teml et al.29 20 UC+IC 40 6 69% (29)
Qasim et al.30 40 CD+UC 40 6 72% (30)
Ansari et al.31 30 CD 40 6 60% (31)
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis. *Response rates were assessed according to 
criteria used by the separate authors.
Table 1 – Efficacy of thioguanine in IBD treatment
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However, these authors did not provide causes for failure 
with first-line thiopurine therapies, or described wheth-
er laboratory abnormalities indicative of liver pathology 
were present prior to 6TG initiation. On the other hand, 
Dutch authors postulated a dose-dependent effect, sup-
ported by studies in which a lower frequency of NRH 
was observed when using a lower dosage of 6TG11,12. This 
dose-dependent effect was confirmed in a large prospec-
tive Dutch cohort of 99 IBD patients using 6TG at a daily 
dose of approximately 20 mg, about half the dose used 
in previous studies. All patients underwent liver biop-
sies, but only four cases (4%) of NRH were identified 
after a median treatment duration of over two years13. 
This prevalence appears not different from that of con-
trol populations14,15. Table 3 summarizes the NRH/SOS 
frequencies observed in different studies and illustrates 
that its occurrence during 6TG therapy is likely to be 
dose-dependent. Furthermore, 6TG-associated NRH 
appeared to be reversible as illustrated by a reduction in 
portal venous pressure after cessation of 6TG therapy16. 
In conclusion, the use of 6TG in IBD is defensible with 
close clinical monitoring, and likely to be preferable to 
conventional thiopurines in many patients provided that 
daily doses are low.
PHARMACOLOGICAL CONSIDERATIONS
If 6MP and 6TG are equally dosed, erythrocyte thiogua-
nine nucleotide (6TGN) concentrations are about tenfold 
higher with 6TG than with MP17. This is believed to be 
due to the more direct conversion of 6TG into 6TGN 
Author n IBD
Daily dose
(mg)
Duration
(months)
Tolerability*
(%)
Ref.
Herrlinger et al.26 37 CD 20-40 6 84% (26)
Dubinsky et al.25  21 CD+UC 20-40 9 81% (25)
Derijks et al.32 32 CD+UC 20-40 2 81% (32)
Bonaz et al.28 49 CD 20 12 90% (28)
De Boer et al.33 95 CD+UC 20-40 12 79% (33)
Teml et al. 34 296 CD+UC+IC 20-40 12 76% (34)
Qasim et al.30 40 CD+UC 40 9 67% (30)
Almer et al.35 23 CD 20-60 > 12 57% (35)
Van Asseldonk et al.36 46 UC 20 > 12 87% (36)
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; IC, indeterminate colitis. *Tolerability rates were assessed according 
to criteria used by the separate authors.
Table 2 – Tolerability of thioguanine in IBD treatment
Author n
TG dose
(mg)
TGN*
(pmol/8x10*8 RBC)
Biopsies
(n)
NRH
(n, %)
Ref
Geller et al.37 111 40 (20-80) 1230 (530-2310) 38 20/38, 53% (37)
Gilissen et al.38 13 19 (6-20) 705 (SD 332) 13 0/13, 0% (38)
Teml et al.34 296 20-40 – 60 16/60, 27% (34)
Ferlitsch et al.16 26 40 (20-80) – 24 6/24, 25% (16)
De Boer et al.39 28 20 (5-40) 564 (SD 278) 28 2/26, 8% (39)
Ansari et al.31 30 40 (20-60) 807 (105-2545) 11 0/11, 0% (31)
Almer et al.35 23 40 (20-60) 600 (99-2488) 2 0/2, 0% (35)
Van Asseldonk et al.36 99 20 (10-24) 463 (SD 270) 99 4/99, 4% (13)
NRH, nodular regenerative hyperplasia; IBD, inflammatory bowel disease; TG, thioguanine; TGN, thioguanine nucleotides; *TGN are expressed 
as medians with their range or mean with standard deviation (SD).
Table 3 – Observed frequencies of NRH in IBD patients using TG
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compared with 6MP and the fact that erythrocytes are 
deficient in the rate-limiting inosine monophosphate de-
hydrogenase enzyme responsible for the conversion of 
6MP into 6TGN18. These differences are nicely illustrated 
by Lancaster et al.19, who showed that if 75 mg of 6MP 
per square meter of body surface was compared to 43 
mg of 6TG per square meter of body surface, then RBC 
6TGN concentrations were around six times higher with 
6TG, whereas 6TGN concentrations in leukocytes, the 
actual target cells, were comparable.
A high erythrocyte 6TGN concentration may be a 
risk factor for SOS because contrasting results on the 
role of thiopurine S-methyltransferase (TPMT) activity 
in 6TG-associated SOS have emerged20,21, which suggest 
that higher TPMT and, therefore, lower 6TGN is less 
damaging. In the treatment of leukemia, methotrexate 
(MTX) is often used alongside 6MP and 6TG. A syner-
gistic effect between MTX and 6MP has been shown in 
vitro and in vivo, and it is believed to be associated to the 
inhibitory effect of MTX on purine de novo synthesis22. 
A similar synergistic effect between MTX and 6TG has 
been hypothesized, but not proven. It may be that such a 
synergism not only increases the therapeutic efficacy but 
also aggravates SOS, which in turn might be diminished 
with 6TG monotherapy or a lower 6TG dose or higher 
TPMT activity.
A NOVEL ANIMAL MODEL OF 6TG
To explore whether 6TG SOS/VOD is idiosyncratic, or 
6TG dose-related, or a class effect of thiopurines, we have 
evaluated in Brisbane, Australia, a novel acute mouse 
model. To date no animal model of 6TG or thiopurine 
related VOD has been published. In particular, VOD 
was screened for, but not detected by Hartford et al. in 
C57BL6 mice23. This report is a brief one because a full 
report is being prepared. C57BL6 mice were gavaged 
with different amounts of 6TG, 6MP, or the methylated 
metabolites of these purine bases. SOS was assessed by a 
blinded observer using a total damage score made up of 
endothelial, hepatocyte and inflammatory cell subscores. 
Peripheral blood was analyzed.  Only 6TG resulted in 
histology damage consistent with SOS. This was apparent 
as early as three days depending on dose, but was consis-
tently seen at 9-14 days when gavaging 6TG 2.5 mg/kg/d.
The major finding was sinusoidal dilatation, as well 
as congestion and damage and loss of central vein endo-
thelial cells, which was apparent at ultrastructural level 
and with staining of endothelium with Von Willebrand 
Factor. There were also subtle liver parenchymal chang-
es apparent on conventional hematoxylin and eosin 
staining, and a marked inflammatory cell infiltrate was 
readily apparent with F4/80 staining for macrophages. 
The effect was very dose-dependent with a dose threshold 
for the histological findings above 0.5 mg/kg/d 6TG at 
14 days. This threshold was lower at 14 days than three 
days, but the threshold did not decrease over a longer 
period of once daily gavage for 28 days, suggesting that 
the effect was not cumulative over this time period. The 
white cell count was reduced in a dose-response man-
ner with white cells being 50% of control at 14 days with 
0.5 mg/kg 6TG once daily gavage (Figure 1). A signifi-
cant further reduction in white cell count was not re-
corded with daily gavage of 0.5 mg/kg 6TG to 28 days.
Figure 1 – Histological changes with 6TG gavage therapy 
over 14 days are dose-dependent.
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FINAL CONSIDERATIONS
The Dutch experience with a large clinical trial and as-
sociated liver biopsy data concerning 6TG treatment of 
IBD are very reassuring, but remain uncontrolled. The 
results of the novel mouse model for 6TG-induced SOS 
are consistent with the Dutch clinical experience. Taken 
together, it is concluded that 6TG therapy at low doses 
is not associated with significant SOS/NRH. Therefore, 
given that there are adverse drug reactions experienced 
by many patients prescribed conventional thiopurines, 
azathioprine or 6-mercaptopurine, we believe that there 
is good reason to conduct a properly powered and con-
trolled prospective clinical trial to compare the clinical 
efficacy and safety of low dose 6TG versus conventional 
thiopurines.
DIRK P. VAN ASSELDONK ET AL.
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